Teva Pharmaceutical Industries (NYSE:TEVA) received a $20.00 price objective from equities research analysts at Credit Suisse Group in a research note issued on Monday. The brokerage currently has a “hold” rating on the stock. Credit Suisse Group’s target price suggests a potential downside of 4.53% from the company’s current price.
Other analysts have also issued research reports about the stock. Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Morgan Stanley upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 price objective on the stock in a research note on Friday, December 15th. Royal Bank of Canada set a $11.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research note on Wednesday, November 29th. Cantor Fitzgerald set a $10.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, December 14th. Finally, Mizuho reiterated a “neutral” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Teva Pharmaceutical Industries in a research note on Friday, November 17th. Eight research analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $21.32.
Shares of Teva Pharmaceutical Industries (TEVA) traded down $0.07 during trading on Monday, reaching $20.95. 10,181,291 shares of the company’s stock were exchanged, compared to its average volume of 27,060,000. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $37.94. The firm has a market cap of $21,020.00, a price-to-earnings ratio of -3.57, a price-to-earnings-growth ratio of 1.48 and a beta of 0.54.
A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Schwab Charles Investment Management Inc. boosted its holdings in Teva Pharmaceutical Industries by 7.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after buying an additional 17,116 shares in the last quarter. Prudential Financial Inc. boosted its holdings in Teva Pharmaceutical Industries by 0.9% during the second quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock worth $2,590,000 after buying an additional 730 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Teva Pharmaceutical Industries by 21.1% during the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock worth $4,125,000 after buying an additional 21,658 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in Teva Pharmaceutical Industries by 5.4% during the second quarter. TIAA CREF Investment Management LLC now owns 666,074 shares of the company’s stock worth $22,127,000 after buying an additional 33,938 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Teva Pharmaceutical Industries by 14.5% during the second quarter. New York State Common Retirement Fund now owns 680,092 shares of the company’s stock worth $22,593,000 after buying an additional 86,371 shares in the last quarter. 51.89% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/23/teva-pharmaceutical-industries-teva-pt-set-at-20-00-by-credit-suisse-group.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
